If I can begin, one of the things we would recommend to the committee is that if you want to look at the question of controlling costs and providing needed services to people, you really have to get into the national pharmaceutical strategy. That has to be there.
Earlier I believe Mr. Brown raised the question about the levers to control costs and dealing with that. Well, the federal government has those levers. They can deal with the question of patent protection and the long, long years of patent protection. They can deal with the question Ms. Silas raised about New Zealand's bulk buying and bringing down costs. That's one of the issues.
If the strategy is to continue to throw money into the private sector, they will bleed the system dry and no one will be able to afford it.